Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.590 -0.040 (-2.45%)

Delayed Quote Updated: 11:00 AM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Innate Pharma to Host Virtual KOL Event on Lacutamab

November 27, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update

November 14, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update

November 07, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023

November 03, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Its Participation to Upcoming Investor Conferences

October 27, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma 2024 Financial Calendar

October 19, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Abstracts Selected for ESMO Congress 2023

October 16, 2023

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023

October 09, 2023

From Innate Pharma SA

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 05, 2023

Via Benzinga

Regulatory Hurdle For Innate Pharma's Blood Cancer Studies ↗

October 05, 2023

The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201...

Via Benzinga

Innate Pharma Provides Update on Lacutamab Clinical Program

October 05, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

September 22, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Reports First Half 2023 Financial Results and Business Update

September 14, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update

August 29, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in Upcoming Investor Conference

August 10, 2023

From Innate Pharma SA

Via Business Wire

First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

July 11, 2023

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023

July 07, 2023

From Innate Pharma SA

Via Business Wire

First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer

June 26, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria

June 16, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma

June 12, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress

June 10, 2023

From Innate Pharma SA

Via Business Wire

Why Shares of Innate Pharma Jumped Thursday ↗

June 08, 2023

The company's collaboration agreement with Sanofi could soon pay off.

Via The Motley Fool

SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

June 08, 2023

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023

June 07, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML

May 26, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in Upcoming Investor Conferences

May 23, 2023

From Innate Pharma SA

Via Business Wire

Outcome of Innate Pharma’s 2023 Annual General Meeting

May 12, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Reports First Quarter 2023 Financial Results and Business Update

May 10, 2023

From Innate Pharma SA

Via Business Wire

Number of shares and voting rights of Innate Pharma as of May 1, 2023

May 09, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Conference Call and Webcast for Q1 Business Update

May 03, 2023

From Innate Pharma SA

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.